DNA methylation biomarkers distinguishing early-stage prostate cancer from benign prostatic hyperplasia

BACKGROUND: DNA methylation markers are considered robust diagnostic features in various cancer types, as epigenetic marks are commonly altered during cancer progression. Differentiation between benign prostatic hyperplasia (BPH) and early-stage prostate cancer (PCa) is clinically difficult, relying...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Stephanie S., Lee, Seung Cho, Lim, Bumjin, Shin, Seung-Ho, Kim, Mee Young, Kim, Sol-Yi, Lim, Hyeyeun, Charton, Clémentine, Shin, Dongho, Moon, Hyong Woo, Kim, Jinho, Park, Donghyun, Park, Woong-Yang, Lee, Ji Youl
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318333/
https://www.ncbi.nlm.nih.gov/pubmed/37409096
http://dx.doi.org/10.1016/j.prnil.2023.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318333/
https://www.ncbi.nlm.nih.gov/pubmed/37409096
http://dx.doi.org/10.1016/j.prnil.2023.01.001

Ejemplares similares